Downside Reaction: Trovagene (TROV), Alexza Pharmaceuticals (ALXA)


Shares of Trovagene, Inc. (Nasdaq:TROV) plunged by more than 20% in the extended session Monday after the company said that its CEO Antonius Schuh and CFO Stephen Zaniboni were fired for cause. According to Trovagene, it has filed a complaint in the Superior Court of the State of California for the County of San Diego against Schuh and Zaniboni for, among other things, breach of fiduciary duty

TROV stock closed at $5.11, down $0.09 (or -1.73%), and 266,691 of its shares exchanged hands during the day

Trovagene, a developer of cell-free molecular diagnostics, has 29.76M Shares Outstanding and TROV stock one-year range from $2.85 to $13.58.  At close on Monday, the company had Market Capitalization (intraday) of $152.06M



The price of Alexza Pharmaceuticals Inc. (Nasdaq:ALXA) stock plummeted over 20% in after-hours trading Monday as the company said that it may be forced to shut down operations under certain circumstances. Alexza believes it has sufficient capital resources until the end of April 2016

The pharmaceutical company posted fourth quarter 2015 revenues of $0.7 million and a net loss of ($3.0) million for the period

ALXA finished the regular session at $0.70, down $0.04 (or -5.28%), with a total volume of 279,107 shares traded

Alexza Pharmaceuticals, which is focused focused on the development of novel proprietary products for acute treatment of central nervous system conditions, has 19.58M Shares Outstanding, Market Capitalization (intraday) of $13.70M and ALXA stock 52-week range is between $0.22 and $2.11


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at